Modulation of human T cells signaling transduction by lovastatin

International Journal of Cardiology

Volumn 140, Issue 1, 2010, Pages 24-33

  Cheng, Shu Meng ^a   Lai, Jenn Haung ^a   Yang, Shih Ping ^a   Tsao, Tien Ping ^a   Ho, Ling Jun ^a   Liou, Jun Ting ^a   Cheng, Cheng Chung ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Atorvastatin; Cytokine; Lovastatin; Monocytes; T cells

Indexed keywords

ATORVASTATIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; MEVINOLIN; TRANSCRIPTION FACTOR AP 1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTERFERON PRODUCTION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; NF-KAPPA B; PYRROLES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTION FACTOR AP-1;

EID: 77949657991     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.10.044     Document Type: Article

References (61)

1. Libby P., and Therous P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
2. Meyer-Sabelleck W., and Brasch H. Atherosclerosis, inflammation, leukocyte function and the effect of statins. J Hypertens 24 (2006) 2349-2351
3. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
4. Sigal L.H. Atherosclerosis: an immunologically medicated (autoimmune?) disease. J Clin Rheumatol 13 (2007) 160-168
5. Szmitko P.E., Wang C.H., Weisel R.D., de Almeida J.R., Anderson T.J., and Verma S. New markers of inflammation and endothelial cell activation: part I. Circulation 108 (2003) 1917-1923
6. Brizzi M.F., Formato L., Dentelli P., et al. Interleukin-3 stimulates migration and proliferation of vascular smooth muscle cells: a potential role in atherogenesis. Circulation 103 (2001) 549-554
7. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340 (1999) 115-126
8. Laurat E., Poirier B., Tupin E., et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104 (2001) 197-202
9. Frostegard J., Ulfgren A.K., Nyberg P., et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145 (1999) 33-43
10. Libby P., and Hansson G.K. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 64 (1991) 5-15
11. Zhou X., Nicoletti A., Elhage R., and Hansson G.K. Transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102 (2000) 2919-2922
12. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
13. Ye H.J., and Zhao S.P. Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects. Med Hypotheses 66 (2006) 495-500
14. Link A., Ayadhi T., Bohm M., and Nickenig G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 27 (2006) 2945-2955
15. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97 (1998) 1440-1445
16. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 (2004) III39-43
17. Riche D.M., and McClendon K.S. Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 64 (2007) 1603-1610
18. Leeper N.J., Ardehali R., Degoma E.M., and Heidenereich P.A. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation 116 (2007) 613-618
19. Jacobson T.A., Miller M., and Schaefer E.J. Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther 29 (2007) 763-777
20. Beaudry D., Stone K.E., Wetherold S., et al. Statin therapy in cardiovascular diseases other than atherosclerosis. Curr Atheroscler Rep 9 (2007) 25-32
21. Thavendiranathan P., Bagai A., Brookhart A., and Choudhry N.K. Primary prevention of cardiovascular diseases with statin therapy a meta-analysis of randomized controlled trials. Arch Intern Med 166 (2006) 2307-2313
22. Weitz-Schmidt G., Welzenbach K., Dawson J., and Kallen J. Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by X-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo. J Biol Chem 279 (2004) 46764-46771
23. Sun D., and Fernandes G. Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production. Cell Immunol 223 (2003) 52-62
24. Brinkkoetter P.T., Gottmann U., Schulte J., van der Woude F.J., Braun C., and Yard B.A. Atorvastatin interferes with activation of human CD4 (+) T cells via inhibition of small guanosine triphosphatase (GTPase) activity and caspase-independent apoptosis. Clin Exp Immunol 146 (2006) 524-532
25. Fehr T., Kahlert C., Fierz W., et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 175 (2004) 83-90
26. Jakobisiak M., Bruno S., Skierski J.S., and Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88 (1991) 3628-3623
27. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., and Friedlander G. 3-Hydroxy-3methylglutaryl coenzyme A inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Circ Res 83 (1998) 683-690
28. Ho L.J., Wang J.J., Shaio M.F., et al. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J Immunol 166 (2001) 1499-1506
29. Lai J.H., Ho L.J., Kwan C.Y., Chang D.M., and Lee T.C. Plant alkaloid tetrandrine and its analog block CD28-costimulated activities of human peripheral blood T cells: potential immunosuppressants in transplantation immunology. Transplantation 68 (1999) 1383-1392
30. Lai J.H., Horvath G., Subleski J., Bruder J., Ghosh P., and Tan T.H. Rel A is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol Cell Biol 15 (1995) 4260-4271
31. Coward W., and Chow S.C. Effect of atorvastatin on TH1 and TH2 cytokine secreting cells during T cell activation and differentiation. Atherosclerosis 186 (2006) 302-309
32. Chandrasekar B., Mummidi S., Mahimainathan L., et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-κB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 281 (2006) 15099-15109
33. Blank N., Schiller M., Krienke S., et al. Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis. J Immunol 179 (2007) 3613-3621
34. Cherfan P., Tompa A., Wikby A., Lofgren S., and Jonasson L. Effects of simvastatin on human T cells in vivo. Atherosclerosis 193 (2007) 186-192
35. Sakamoto T., Kojima S., Ogawa H., et al. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction. Circ J 71 (2007) 1348-1353
36. Istvan E. Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atherosclerosis Supplements 4 (2003) 3-8
37. Wang I.K., Lin-Shiau S.Y., and Lin J.K. Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharm & Toxicol 86 (2000) 83-91
38. Buono C., Come C.E., Stavrakis G., Maguire G.F., Connelly P.W., and Lichtman A.H. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol 23 (2003) 454-460
39. Libby P., Sukhova G., Lee R.T., and Galis Z.S. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 25 Suppl 2 (1995) S9-S12
40. Harvey E.J., and Ramji D.P. Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?. Cardiovasc Res 67 (2005) 11-20
41. Buttice G., Miller J., Wang L., and Smith B.D. Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Cir Res 98 (2006) 472-479
42. Steffens S., and Mach F. Anti-inflammatory properties of statins. Semin in Vasc Med 4 (2004) 417-422
43. Schroechsnadel K., Frick B., Winkler C., and Fuchs D. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 4 (2006) 205-213
44. Johnson D.R., Hauser I.A., Voll R.E., and Emmrich F. Arterial and venular endothelial cell costimulation of cytokine secretion by human T cell clones. J Leukocyte Biol 63 (1998) 612-619
45. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
46. Hansson G.K. Regulation of immune mechanisms in atherosclerosis. Ann N Y Acad Sci 947 (2001) 157-165
47. Davenport P., and Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 163 (2003) 1117-1125
48. King V.L., Szilvassy S.J., and Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice. Arterioscler Thromb Vasc Biol 22 (2002) 456-461
49. Leskinen M.J., Kovanen P.T., and Lindstedt K.A. Regulation of smooth muscle cell growth, function and death in vitro by activated mast cells-a potential mechanism for the weakening and rupture of atherosclerotic plaques. Biochem Pharmacol 66 (2003) 1493-1498
50. Adhikari N., Charles N., Lehmann U., and Hall J.L. Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury. Curr Atheroscler Rep 8 (2006) 252-260
51. Karin M., Liu Z., and Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 9 (1997) 240-246
52. Moon S.K., Cho S.H., Kim K.W., Jeon J.H., Ko J.H., and Kim BY Kim C.H. Overexpression of membrane sialic acid-specific sialidase Neu3 inhibits matrix metalloproteinase-9 expression in vascular smooth muscle cells. Biochem Biophys Res Commun 356 (2007) 542-547
53. Bea F., Kreuzer J., Preusch M., et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 26 (2006) 2787-2792
54. Chen D.M., Cai X., Kwik-Uribe C.L., Zeng R., and Zhu X.Z. Inhibitory effects of procyanidin B (2) dimer on lipid-laden macrophage formation. J Cardiovasc Pharmacol 48 (2006) 54-70
55. Brand K., Page S., Rogler G., et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 97 (1996) 1715-1722
56. Ghosh S., and Karin M. Missing pieces in the NF-κB puzzle. Cell 109 (2002) S81-S86 Suppl
57. Baldwin Jr. A.S. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107 (2001) 3-6
58. Chiba T., Kondo Y., Shinozaki S., et al. A selective NF kappaB inhibitor, DHMEQ, reduced atherosclerosis in apoE-deficient mice. J. Atheroscler. Thromb. 13 (2006) 308-313
59. Cheng W.L., Lii C.K., Chen H.W., Lin T.H., and Liu K.L. Contribution of conjugated linoleic acid (CLA) to the suppression of inflammatory responses through the regulation of the NF-[kappa]B pathway. J Agric Food Chem 52 (2004) 71-78
60. Zhu Y., Lin J.H., Liao H.L., et al. LDL induces transcription factor protein-1 (AP-1) in human endothelial cells. Arterioscler Thromb Vasc Biol 18 (1998) 473-480
61. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150